Result of General Meeting

Oxford BioMedica (LSE: OXB), a biopharmaceutical company developing gene-based medicines and therapeutic vaccines, announces that all resolutions proposed were duly passed at its General Meeting, held today in London.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 156 to 158 of the prospectus dated 13 December 2010).

In accordance with the Company's obligations under Listing Rule 9.6.2, copies of the resolutions passed at the General Meeting have been submitted to the National Storage Mechanism and will shortly be available for viewing at http://www.hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (10 December 2010) there were 544,875,557 1p ordinary shares in issue, each carrying one vote per share.

Resolution

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

Votes

Against

Votes

Withheld

Total

votes cast

Result

Ordinary resolutions

1

165,363,035

602,268

379,129

92,215

786,126

166,436,647

Passed

2

165,123,318

862,721

379,129

53,468

804,137

166,418,636

Passed

4

97,441,672

648,135

379,129

160,484

68,593,353

98,629,420

Passed

5

165,096,664

657,295

379,129

199,525

890,160

166,332,613

Passed

Special resolution

3

164,846,001

640,898

379,129

416,975

939,770

166,283,003

Passed

-Ends-

For further information, please contact:

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tel: +44 (0)1865 783 000

Singer Capital Markets Limited

Shaun Dobson/ Claes Spång

Tel: +44 (0)20 3205 7500

Media/Financial Enquiries:

Emma Thompson/Rob Newman/Amber Bielecka

M:Communications

Tel: +44 (0)20 7920 2345

US Enquiries:

Simon Harnest

The Trout Group LLC

Tel: +1 (646) 378 2900

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk